Plant Name: Saussurea costus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| GABBR1; | |
| BLM; HPGD; GFER; HSD17B10; ALOX15; ALDH1A1; | |
| TRPA1; | |
| GABRR1; | |
| MAPK1; | |
| CA12; CA9; CA7; | |
| PPARA; PPARD; PPARG; | |
| CASP1; CASP7; | |
| TLR2; | |
| HIF1A; TP53; | |
| KMT2A; | |
| SLC6A11; SLC6A1; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; | |
| XDH; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.563E-07 | 1.299E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 5.480E-07 | 3.314E-04 | CASP1, CASP7, MAPT, PPARG, XDH |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 2.354E-06 | 1.091E-03 | CASP1, FABP4, FFAR4, HIF1A, LMNA, MAPK1, MAPT, PPARA, PPARD, PPARG, TLR2, TP53, XDH |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.144E-06 | 1.369E-03 | CA12, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 8.929E-06 | 3.136E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.554E-05 | 4.377E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.568E-05 | 4.377E-03 | HIF1A, PPARD, TP53 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.661E-05 | 4.521E-03 | MAPK1, MAPT, PPARA, PPARG, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.660E-05 | 4.521E-03 | ALDH1A1, ALOX15, BLM, CA7, CASP1, CASP7, FABP2, FABP3, FABP4, FABP5, GFER, HIF1A, HPGD, KMT2A, LMNA, MAPK1, MAPT, PPARG, SMN1, SMN2, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.809E-05 | 4.804E-03 | FABP3, FFAR1, PPARG, TLR2 |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 2.093E-05 | 5.190E-03 | CASP1, FABP4, HIF1A, TLR2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.151E-05 | 5.190E-03 | BLM, CA12, CA7, CA9, KMT2A, PPARA, PPARD, PPARG, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.256E-05 | 5.190E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 2.256E-05 | 5.190E-03 | SLC6A1, SLC6A11 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 3.755E-05 | 7.937E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 4.249E-05 | 8.896E-03 | BLM, CASP1, HPGD, KMT2A, MAPK1, MAPT, PPARG, SMN1, SMN2, TP53, TRPA1, XDH |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.795E-05 | 9.759E-03 | CA12, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 4.933E-11 | 7.203E-09 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 2.304E-05 | 6.727E-04 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.235E-05 | 6.727E-04 | MAPK1; PPARG; TP53 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.225E-06 | 3.084E-04 | CA12; CA7; CA9 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.235E-05 | 6.727E-04 | CYP1A2; ALOX15; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.411E-04 | 2.830E-03 | CASP7; LMNA; MAPK1; TP53 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.551E-04 | 2.830E-03 | CASP7; CASP1; TLR2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.838E-04 | 3.766E-03 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.787E-04 | 3.766E-03 | MAPK1; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.548E-04 | 3.766E-03 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.805E-04 | 5.650E-03 | MAPK1; TP53; HIF1A; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.386E-04 | 5.617E-03 | GABBR1; MAPK1; PPARA; TSHR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.797E-04 | 8.027E-03 | MAPK1; PPARG; HIF1A; TP53; PPARD |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.688E-04 | 4.367E-03 | HPGD; KMT2A; PPARG; TP53 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.888E-04 | 4.367E-03 | CASP7; CASP1; MAPK1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.453E-03 | 1.248E-02 | MAPK1; TP53; HIF1A |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.666E-03 | 2.008E-02 | MAPK1; TP53; TLR2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.046E-03 | 1.659E-02 | MAPK1; PPARA; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.074E-03 | 2.833E-02 | MAPK1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.390E-03 | 2.787E-02 | MAPK1; TP53 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.751E-03 | 2.008E-02 | MAPK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.074E-03 | 2.833E-02 | FABP4; TSHR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.253E-03 | 2.833E-02 | MAPK1; PPARD |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 4.226E-03 | 2.787E-02 | CASP1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.451E-03 | 2.400E-02 | CYP3A4; XDH |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.781E-03 | 3.090E-02 | MAPK1; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.805E-03 | 2.922E-02 | MAPK1; HIF1A |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 6.187E-03 | 3.011E-02 | MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.984E-03 | 3.090E-02 | MAPK1; TP53 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 5.253E-03 | 2.833E-02 | CASP1; MAPK1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.244E-02 | 4.324E-02 | MAPK1; MAPT; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 8.043E-03 | 3.260E-02 | MAPK1; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 6.984E-03 | 3.090E-02 | MAPK1; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.486E-03 | 3.260E-02 | MAPK1; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.434E-03 | 2.833E-02 | CYP1A2; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.611E-03 | 3.260E-02 | CYP1A2; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.241E-02 | 4.324E-02 | MAPK1; TP53 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.551E-02 | 4.797E-02 | GABBR1; GABRR1; TSHR |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.486E-03 | 3.260E-02 | CYP1A2; CYP3A4 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 8.486E-03 | 3.260E-02 | MAPK1; TLR2 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.377E-02 | 4.568E-02 | PPARG; TP53 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.519E-02 | 4.797E-02 | GABBR1; MAPK1 |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 1.294E-02 | 4.394E-02 | GABBR1; GABRR1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.503E-05 | 8.523E-04 | CYP1A2; XDH |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.577E-02 | 4.797E-02 | MAPK1; HIF1A |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.162E-02 | 4.242E-02 | CASP1; MAPK1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.061E-02 | 3.972E-02 | CYP1A2; CYP3A4 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.577E-02 | 4.797E-02 | GABRR1; MAPK1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.637E-02 | 4.867E-02 | MAPK1; HIF1A |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.728E-02 | 4.946E-02 | MAPK1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.667E-02 | 4.867E-02 | MAPK1; TLR2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; PPARG; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA9; MAPK1; TLR2 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PPARG |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9; MAPK1; TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |